
(Neuro) Scientist @Episteme | Prev PhD @MIT @MediaLab @Neuralink
San Francisco
Joined February 2012
- Tweets3.7K
- Following649
- Followers581
- Likes22.1K
Pinned Tweet
Excited to share our work on the myoneural actuator - a 'living' implant that reprograms your body's own muscle into an actuator to restore movement in paralyzed organs.
@MIT @medialab @mcgovernmit
Even Zizek is pilled: slavoj.substack.com/p/digger…
Digger pilled Peter Kagan
The first time I walked out genuinely shell-shocked overwhelmed by the film's complexity it's powerful imagery and those huge performances. I was awestruck the first time. Today I fell in love with it anew. To my mind it belongs among the masterpieces.
71
Indeed this was the year
teapaw.org/nobelprize/status/2107…
3
173
Qué es la optogenética, la técnica que ganó el Nobel 2026 milenio.com/ciencia-y-salud/… via @Milenio
169
“You just got your voice back”
Incredible work @SammyNio @tuxedocat
Through the VOICE trial, Terry is using his Neuralink implant to help fine-tune a brain-to-voice interface for himself and others who can’t speak. He trained the algorithm first by miming speech as best he could, then by simply thinking the words and hearing them come out in his own natural voice.
Powered by Grok Voice from @spacexai
2
603
Thrilled to share I’ve joined @episteme as a principal investigator. Episteme is a new type of R&D company, designed to pursue translational science. I’m incredibly grateful for the opportunity to keep doing science, and to help build a new model for how it’s done.
Today, we're announcing @episteme, a new type of R&D company that recruits exceptional scientists to pursue high-impact ideas.
Science isn’t bottlenecked by the availability of talent, but by places where they can do their best work.
Scientific progress has driven human flourishing: extending lifespans, lifting billions from poverty, and expanding our understanding of the universe.
But history is littered with transformational ideas that were overlooked in their time. That problem is still acute today: too much promising talent remains uncultivated, and remarkable ideas die in the lab or are filtered out by misaligned incentives.
Today, scientists face suboptimal paths for translating their research into impact: academia is famously risk-averse and incentivizes publications and winning grants vs. translational research. Industry is too often focused on short‑term incentives. And startups lack the substantial capital, expertise, and complex infrastructure needed to deliver long-term scientific progress.
On top of that, recent funding cuts in the US mean the overall supply of ideas is decreasing. Put together, the global scientific production system is operating at a fraction of its capacity.
How Episteme operates is different: we identify great scientists who can meaningfully benefit humanity, but who aren’t supported efficiently within traditional institutions today. Researcher by researcher, we work with them to determine the bespoke resources, operational support, and environmental conditions to execute on their research. We bring them together in-house, and provide those resources to ensure that their breakthroughs are deployed for real-world impact.
We’ve already assembled an amazing team of operators, ranging from the Gates Foundation, DeepMind, ARPAs, DoE – just to name a few – and researchers who are pursuing important problems across physics, biology, computing, and energy. Our team has spoken to hundreds of researchers across disciplines and geographies to understand the limitations they’re facing and what can be done better, and designed Episteme for them.
We’re backed by individuals like @sama, Masayoshi Son, and other long-term partners who share our mission of enabling ambitious science for tangible human impact.
About me: I started working as a researcher 9 years ago, on problems ranging from AI-driven drug discovery to developing brain-machine interfaces. It was that experience that led me to realize that so many scientists with great potential to change the world don’t have access to opportunities equal to their capacities.
@sama and I believe that much better science should happen for humanity, and that a new engine is needed to support that. We decided to cofound Episteme together, and I am incredibly grateful for Sam’s unwavering support as a thought partner and founding investor.
Our conviction is that by supporting the right people with the right incentives, we're set to generate breakthrough discoveries to benefit humanity. We cannot rely on the course of history to shape scientific progress; we need to proactively shape the system by supporting the most talented people with the right resources and incentives.
If you are a physician, physician-scientist, immunologist, neuroscientist or neural engineer, interested in developing neural interfaces that regulate immunity to treat some of the most devastating diseases — and in figuring out how to get them to patients — please reach out!
1
70
Venture partner but for FROs… damn! This looks fun!
We're hiring.
Think: Sr partner at a venture incubator, but the outputs are Focused Research Organizations
Form the thesis, find the founders, build the boards, launch the org
AI resilience: bioresilience, cyber-physical systems, epistemic infrastructure, compute governance
3
151
Guillermo Herrera-Arcos retweeted
In May, Vijeta and I had our wedding in Cambridge Commons with hundreds of you all.
In June, her grandfather suddenly passed away.
In July, her papa was diagnosed with stage IV cancer and a brain tumor. He is 58. He was at our wedding, already symptomatic, and none of us knew.
We thought we'd be planning a honeymoon. Instead life threw a heavy punch.
But we’re not ones to take a fight lying down. The honeymoon is on hold. We're cashing in our savings and going all in.
And still, we can't help being optimistic. We can't help trying hard. We’re hoping the standard treatment will lead to remission. But if need be, Burhan has said for years that if cancer is ever cured, it'll be cured in Kendall Square and make ourselves a small part of that story. We want to understand this disease as deeply as we can (we’ve been deeply moved by the stories of Sid Sijbrandij and Ben Sasse), and if we have to build a new treatment ourselves, that's what we'll do.
Before the clinical details, I want you to know who he is to Vijeta and us.
He held Vijeta for hours in the hospital the day she was born, just staring. He stood outside her school for six hours in the summer heat because she sneezed one morning in first grade. He took her to the park every single day for sixteen years. For 28 years he's walked his neighborhood checking on every old uncle, making sure none of them go without a friend. He's a professor whose students and colleagues fight for him in ways I've rarely seen even family manage.
Here's where we are.
Surgeons removed the tumor from his cerebellum on July 13 and he came through it well. It's metastasis. It's a cancer that started somewhere else in his body and traveled to his brain, and we don't know yet where it started. Treatment depends on knowing. And it's incredibly fast dividing. Every single day matters.
Right now we're starting radiation on the brain and hunting for the primary.
Vijeta is a researcher. I'm an engineer. We've spent the last four weeks reading everything we can find, and what we found was not despair.
Here's where you come in. Five things, and any one of them helps.
1. We have three tissue blocks from the surgery. One has been analyzed. One is at a genomics lab in Hyderabad running a full genomic profile. The third is unspent and we're holding it. If you know a lab that can run something those two won't, tell us.
2. If you've seen this before, a single brain metastasis with an unknown primary, we want your instinct. Assume we haven't heard of the thing you're about to suggest.
3. Introductions. Doctors, researchers, labs, clinical trials, anyone working on cancer of unknown primary.
4. If you have access to a frontier AI model, that’ll be helpful as we’re trying to get an incredible amount of data points and the processing power will be very helpful.
5. Share this on socials or forward this to the one person you know who might have an answer.
We're publishing all of it as we go. The scans, the pathology, the decisions, the reasoning behind the decisions, and the ones that turn out to be wrong. The full clinical detail is in the post below, including the immunohistochemistry panel.
vijetaandburhan.substack.com…
If you have answers, suggestions, introductions or anything else send us an email to: [email protected]
PS. I expect my City Council work and State Senate campaign to continue as normal. Vijeta, on the other hand, has taken an extended leave from her job. We expect to pay for most of this treatment out of pocket, and we're restructuring our lives around it as we go. Please have some grace with us while we do. We'd appreciate the kindness.
Guillermo Herrera-Arcos retweeted
VOX: Voice Operator eXperience
A stethoscope for your voice: works at low volume and in loud environments.
Across all your devices and agents.
Hardware that looks 🔥🔥
Replying to @augmentaltech
MouthPad and VOX introduce Skinware, technology worn where the body meets the machine.

ALT Two transparent Augmental devices side by side on a white background. Left: Vox, a small round pendant on a white cord with visible internal electronics, a white circular component, and an orange accent. Right: MouthPad^, a clear custom-fit dental retainer with a gold flexible circuit sensor pad across the palate, gold serpentine traces, and battery modules at the rear molars.
1
215
Guillermo Herrera-Arcos retweeted
In response to @POTUS's call for a revival of America's scientific enterprise, today I’m releasing Science: A New Golden Age.
This report is a blueprint for renewing American scientific leadership for the 21st century.
Guillermo Herrera-Arcos retweeted
This standing ovation totally brought me to tears.
On Thursday, my dad (stage 4 pancreatic cancer) started a Revolution Medicine trial building upon these results — RMC 5127, which uses the drug celebrated here, Daraxonrasib, with another drug targeting his specific KRAS mutation, G12V.
He’s nearly 2 years into his fight with pancreatic cancer and we have personally felt the impact of this watershed moment. It is a lifeline.
To the incredible, stalwart, brilliant researchers and folks bringing these discoveries to life - thank you. Thank you thank you thank you.
Guillermo Herrera-Arcos retweeted
The Mexican Press Agency @mexi_press spotlights Yang Center for Bionics postdoc @Guillermonics, who is developing incredible “living” implants that could one day restore movement and function to paralyzed organs. Read the feature linked below!
@medialab @mcgovernmit
Guillermo Herrera-Arcos retweeted
i used to think i had a pretty intuitive grasp of the immune system until i met an actual immunologist. theres a lot of training that goes on here that the average person doesn’t know about. the best schools are in eastern europe. there, you wake up each morning at 11am sharp, and explain HLA alleles, or something of the sort, to a child who barely understands english. you get 5 minutes. if the child is still confused at the end, you are thwacked with a stick. this continues until evening dinners. during dinners, you stand up, swallow a toxin of your choice, and draw a molecular diagram of what is happening to you. at least until you cant stand anymore. then you get the antitoxin, but how much antitoxin you get is dependent on how accurate the diagram was. throughout all this, you also need to actively trade a stock portfolio of immunotherapy and autoimmune biotechs. being in the red for longer than a month is grounds for automatic expulsion
many cant cut it. but the select few that make it out are reborn, made unstoppable, possessing an iron will, grit, and a mind with no peer. at the end, they are sent off back into the world to serve. you can find them all around you, though they keep a low profile. if you’re ever lucky enough to meet one, make sure to thank them for their service
Guillermo Herrera-Arcos retweeted
The possibilities here are amazing. news.mit.edu/2026/turning-mu…






















